Entrada Therapeutics, Inc. (TRDA): Cash & Equivalents
$90.39M
As of 2025-12-31
$99.28M
As of 2026-06-30
+26.0%
3-year compound annual growth
+18.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $90.39M | -10.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $101.21M | +49.7% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $67.60M | +49.7% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $45.16M | -84.5% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $291.06M | +645.5% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $39.05M | n/a | 2022-03-15, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $90.39M | -10.7% |
| Celularity Inc (CELU) | 2025-12-31 | $6.17M | +736.7% |
| Alumis Inc. (ALMS) | 2025-12-31 | $89.67M | -47.1% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $27.14M | +20.8% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $490.00M | -36.5% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $80.88M | +45.8% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $204.99M | +130.8% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $5.63M | -58.2% |
| Scynexis Inc (SCYX) | 2025-12-31 | $21.26M | +32.4% |
Compare TRDA, CELU, ALMS, CUE side by side · Screen every company in Pharmaceutical Preparations ↗